FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-028	7				
Estimated average burden						
nours per response	e 0.	5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person * Cranston Lynda Sarah				2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) SUITE 720-999 WEST BROADWAY				3. Date of Earliest Transaction (Month/Day/Year) 06/30/2017						Office	er (give title belo	ow)	Other (specify	pelow)	
(Street) VANCOUVER, A1 V5Z 1K5			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
(Instr. 3) D		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Yea	f Code (Instr. 8)			4. Securities Acquire (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect	Beneficial Ownership		
					C	Code V		Amoun	(A) or (D)	Price				(I) (Instr. 4)	
Common	Stock		06/30/2017		J	(1)		71	A	\$ 3.2 (1)	2 2,415			I	Note (2)
indirectly.				Derivative Securit		quire	conta the fo d, Dis	ained i orm dis	n this fo splays a of, or Be	orm ai a curr neficia	e not required the not required to the notice of the notic	uired to re d OMB co	nformation espond un ntrol numb	less	EC 1474 (9- 02)
	-			2.g., puts, calls, w								I			
	2. 3. Transaction Conversion Date or Exercise (Month/Day/Y Price of Derivative Security				of		6. Date Exercisable and Expiration Date (Month/Day/Year)		An Un Sec	Citle and count of derlying urities str. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct (or Indir	Beneficia Ownershi y: (Instr. 4) D) ect	
				Code V	(A)	(D)	Date Exerc	cisable	Expiration Date	on Titi	Amount or e Number of Shares				

Reporting Owners

Powerfine Community (Addition	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Cranston Lynda Sarah SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	X						

Signatures

/s/ Lynda Cranston	07/05/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
- (2) Shares are held by J.G. Cranston & Associates, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

